DIA 2024 Global Annual Meeting

Without patients, there are no trials. Without the sites to conduct studies, there are no trials. This simple truth drives inclusivity initiatives, and the surge in technology "solutions". In this panel discussion, we bring together voices from across the clinical trial ecosystem and demonstrate how teamwork comprised of medical expertise, market access insight, patient voice, site advisory boards, and technology partnerships work together with developers & CROs to make teamwork the dream work.

Refreshments and snacks provided

Panel discussion lead by: Amy Hadley, VP and Head of Business Operations, Fortrea and joined by our below panelists.

AI can help optimize operations, strengthen patient privacy, and improve data quality while reducing risks of human error in clinical trials. However, AI must be used responsibly and governed by the highest ethical principles with regard for data privacy and reducing bias in algorithm performance. Delve into the transformative role of AI in clinical trials: current industry status, common misconceptions, proactively tackling bias and navigating the evolving regulatory landscape.

Brian Dolan, VP, Artificial Intelligence & Machine Learning at Fortrea, is one of the panelists on this session, bringing his long history of practical AI/ML solution building to the discussion.

Paulla Dennis, Senior Director/Rare Diseases, Advanced Therapies, & Pediatrics at Fortrea, will be contributing to the session by speaking on Ethical, Clinical, and Timing Considerations for Administering Cell and Gene Therapies in Neonates and Early Childhood